Mediwatch is a small company destined to become a much bigger fish by the time this year is out. Mediwatch are already a market leader in urological medical diagnostics equipement and are currently exporting their products throughout the UK, Canada, Europe, India and Japan. That doesn't leave much of the globe left for them to capture - until you remember the good ol' US and China. These are the two massive markets which are destined to be added to MDW's export client portfolio by the end of 2005.

Website: www.mediwatch.com

The company is currently heavily undervalued. This is probably because Mediwatch's speciality is not a very glamourous business to be in as their equipment is used extensively to diagnose prostate cancer in men and other nasty urological conditions affecting both men and women. However, don't let that put you off investing in these guys. This is big business and is growing at an exponential rate as more and more people globally become health-aware as they get older. Mediwatch normally supply their products through to global markets via distribution agreements. They already have the best of distribution partners in the well known US medical distributor CR Bard who supply Canada and Europe and GE Medical who supply Japan. The UK business is handled by Mediwatch's own dedicated sales team. US FDA approval was gained for MDW's products at the start of last year, however a whole year of US legal wrangling meant that they were unable to seek a suitable partner for the crucial distribution agreement until the start of this year. This distribution agreement is expected by the board to have a "significant effect" on the share price so they are reluctant to give any clues as to when it will be signed, sealed and delivered. The general consensus is that this US distribution agreement will be announced in July/August. In China and Hong Kong, MDW have done things the other way round. They have set up distribution agreements with major Asian medical equipment distributors and have stock already out there waiting to sell into the markets - all they are waiting for is SDA approval (which is a "rubber stamp") from the Chinese authorities - this can take anything up to 12 months to come through and MDW applied during Autumn 2004 - so even more good news coming soon this year. Epidemiological data from British Association of Urology conference last year: On average 30-45% of all men between the age of 50 and 70 have at least one PSA test per year in the US / Italy / Australia. If that's not enough to convince you to invest a few hard earned coppers in MDW, they are also developing a PSA stick test product (PSAWatch) which is revolutionary and causing some excitement in medical circles. This product can also be adapted (at very low cost) for a whole spectrum of medical disciplines from Cardiology to Veterinary Practice! This product is likely to be released in the next few weeks. Philip Stimpson the CEO has said that this product is going to be their "gold mine" - I'm sure it will prove to be ours too.

Well what's another few months eh.
Of greater interest to me is the fact that they've decided to change their financial year end to 31 October 2006.

keeps the losses for the year at a lower level el chocco :-)

Is this a fill yer boots job?

;-0

fill yer hole more like worzel

I could worry about you, ginge ;)

wibble wibble hatstand

Must be a fill yer pants job then. ;-)))

Obviously move of year end to October is that 2007 results will then be a full year as a producer with the new acquisistion embedded. More likely then to show a maiden profit for a year than only a H2 profit. As a supplier to Bard and Medtronic with their own products and now licence of Medtronics technology and the increased distribution network MDW should become a profitable outfit.
Sp over the next month whilst we wait the EGM? Depends on current investors views of the deal but it is a no-brainer. SP over the next year should be higher as they become a producer and developer rather than developer with some sales.

well said andy
I am here for the long term happy to hold and will be increasing holding
:-)

treble u still short ?

leeds yes you know I am....is the downtrend still intact?

Afternoon all.
I keep forgetting about this thread,all looking good and ready for a new era in MDW's history :-)

MDW having a good morning.

Over a Million bought so far.......

Must be Treble closing his short. ;-0

lol

Was an interesting day though.

This share was mentioned in the Penny sleuth newsletter today with a recommendation to keep an eye on it not to buy.
From the chart it looks like it will drop further unless there is major news, only sells so far today. Hope Andy dumped SEO many many months ago at least MDW do not have SEO's directors which is a major point in it's favour.

rpaco, if you are concerned about me don't be. You will see from SEO boards (maybe not most of it is now tosh!!) that I bought between 4p-6p and sold for 21p last October. I tried to warn others but!!!!!!!!!!!!!!!!
Still happy with my holding in MDW, this year will be pivotal.

Pennysleuth...Tom Bulford.....Fleetstreet Publications...

Prostate disease continues to rise - this little company could be in big demand

The next stock that caught my eye specialises in urology equipment. Their star product is Multiscan, which provides clinicians with mobile and real time ultrasound imaging, accurate measurement and organ volume calculation of the bladder, kidney and prostate.

Multiscan however, is most certainly not a one trick pony, as it can also be used in pathology, vascular and veterinary medicine. The demand for urology services is growing, as the incidence of prostate disease rises coupled with the growing need for prostate specific antigen (PSA) tests - particularly in a primary care environment.

This company can reduce the time taken to produce results from days to minutes, and enable testing for prostate disease to be conducted outside expensive laboratories using PSAwatch(tm) and the Bioscan(tm) reader.

The stock I'm talking about is Mediwatch (MDW) and it's another one that should be worth monitoring over the months ahead. Keep an eye on it - and I might well look at it further, once I've checked out the company in more detail.

Here's the News,

Mediwatch PLC
11 December 2006


Issued on behalf of Mediwatch plc
Date: Monday 11th December 2006

Immediate Release

Mediwatch plc
Completion of Acquisition, New Products and Trading Update

Mediwatch plc (AIM; MDW) ('Mediwatch' or 'Company'), the high-tech medical
diagnostic equipment manufacturer and supplier announces that it completed the
agreement to purchase certain stock and to license certain intellectual property
('Acquisition') relating to urology diagnostics from Medtronic A/S ('Medtronic')
on 8 December 2006.

The value of the assets to be purchased has been agreed at US$2.0 million (1.1
million), which relates to stock, and will be satisfied by monthly payments,
which will be based on the amount of stock utilised but subject to minimum
monthly payments of US$100,000 (54,000).

The establishment by Mediwatch of a US-based sales and marketing operation to
service the existing Medtronic North American customer base is progressing well
and the directors of Mediwatch expect this business to be fully operational by
the end of the first calendar quarter of 2007.

Also as part of the acquisition, Mediwatch is working to establish independent
relationships with Medtronic's world-wide distribution network. In anticipation
of the successful acquisition of the Urodynamic division, Mediwatch and
Medtronic have already co-hosted an international dealer conference to introduce
the established Medtronic distributors to the new and extended range of
Mediwatch equipment.

New Products
The acquisition of the Medtronic Urodynamics business brings a number of
complementary and well established capital equipment and disposable products to
Mediwatch's existing range.

In addition, work on Mediwatch's new products in development is progressing
well:-

PSAwatchTM - the quantitative point of care diagnostic test for prostate disease
is reaching the final stage in the application for CE approval which is expected
to be received during February 2007. Sales into the European market are
therefore expected to commence in the second calendar quarter of 2007. The US
FDA approval is being targeted for Summer 2007 and the directors anticipate that
marketing in the US will commence in the Autumn.

Portascan+TM (Portascan Plus) - the second generation of the well established
ultrasound system for imaging the bladder and kidneys is nearing completion. It
will be marketed early in 2007.

MultiscanTM - Work on the higher powered, desk-top version of the innovative
MultiscanTM is on track. This higher specification version of the MultiscanTM
will provide clinicians with a device suitable for detailed assessment of
bladder, kidney and prostate disorders in a hospital or clinic environment. As
with the complete family of Mediwatch products, it will link wirelessly to other
devices. It is anticipated that the desk-top derivative of the MultiscanTM will
provide a platform for several future products and is expected to be available
early 2008.

Trading Update
Mediwatch announced when it released the results for the 12 month period ended
30 April 2006 that it had changed its financial year end to 31 October and
therefore extended its trading period to 31 October 2006. Trading in the third
six month period continued in-line with trading in the financial period ended 30
April 2006.

The new financial year has started in-line with management expectations and
budgets. The directors expect that there will be an improved trading performance
in the current year following the completion of the acquisition of the Medtronic
Urodynamics business, the establishment of the US marketing operation and the
on-going new product development programme. Overall, the Company is in an
excellent position to exploit and benefit from the opportunities it has already
identified.

The preliminary results announcement for the 18 month period ended 30 October
2006 is expected to be announced on 29 January 2007. Mediwatch has commissioned
an in-depth research report from an independent research house which will be
released shortly after the preliminary announcement and will be available on the
Company's website.

Enquires:
Mediwatch plc Citigate Dewe Rogerson Ltd
Philip Stimpson, CEO Fiona Tooley/Katie Dale
Kevin Middis, Finance Director Tel: 0121 455 8370
Tel: 01788 547888 Mobile: (FMT) 07785 703523

www.mediwatch.com




This information is provided by RNS
The company news service from the London Stock Exchange